297 related articles for article (PubMed ID: 28691187)
1. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients.
Moreno-Arrones OM; Becerra A; Vano-Galvan S
Clin Exp Dermatol; 2017 Oct; 42(7):743-748. PubMed ID: 28691187
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
Sato A; Takeda A
J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
[TBL] [Abstract][Full Text] [Related]
3. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
4. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system.
Shin JW; Chung EH; Kim MB; Kim TO; Kim WI; Huh CH
J Dermatol; 2019 Feb; 46(2):139-143. PubMed ID: 30536893
[TBL] [Abstract][Full Text] [Related]
6. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up.
Rossi A; Cantisani C; Scarnò M; Trucchia A; Fortuna MC; Calvieri S
Dermatol Ther; 2011; 24(4):455-61. PubMed ID: 21910805
[TBL] [Abstract][Full Text] [Related]
7. Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia.
Yoshitake T; Takeda A; Ohki K; Inoue Y; Yamawaki T; Otsuka S; Akimoto M; Nemoto M; Shimakura Y; Sato A
J Dermatol; 2015 Jul; 42(7):735-8. PubMed ID: 25903108
[TBL] [Abstract][Full Text] [Related]
8. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss).
Shapiro J; Kaufman KD
J Investig Dermatol Symp Proc; 2003 Jun; 8(1):20-3. PubMed ID: 12894990
[TBL] [Abstract][Full Text] [Related]
9. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
[TBL] [Abstract][Full Text] [Related]
10. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.
Rossi A; Mari E; Scarno M; Garelli V; Maxia C; Scali E; Iorio A; Carlesimo M
Int J Immunopathol Pharmacol; 2012; 25(4):1167-73. PubMed ID: 23298508
[TBL] [Abstract][Full Text] [Related]
11. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
Price VH; Menefee E; Sanchez M; Ruane P; Kaufman KD
J Am Acad Dermatol; 2002 Apr; 46(4):517-23. PubMed ID: 11907500
[TBL] [Abstract][Full Text] [Related]
12. Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study.
Lin JH; Chen WC
Kaohsiung J Med Sci; 2002 Aug; 18(8):379-85. PubMed ID: 12476680
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
Gupta AK; Charrette A
J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
[TBL] [Abstract][Full Text] [Related]
15. Androgenetic alopecia: an update.
Kaliyadan F; Nambiar A; Vijayaraghavan S
Indian J Dermatol Venereol Leprol; 2013; 79(5):613-25. PubMed ID: 23974579
[TBL] [Abstract][Full Text] [Related]
16. Androgenetic Alopecia in Gender Minority Patients.
Marks DH; Senna MM
Dermatol Clin; 2020 Apr; 38(2):239-247. PubMed ID: 32115134
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
[TBL] [Abstract][Full Text] [Related]
18. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G
Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036
[TBL] [Abstract][Full Text] [Related]
19. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
Camacho FM; García-Hernández MJ; Fernández-Crehuet JL
Br J Dermatol; 2008 May; 158(5):1121-4. PubMed ID: 18363752
[TBL] [Abstract][Full Text] [Related]
20. Finasteride and androgenic alopecia; from therapeutic options to medical implications.
Motofei IG; Rowland DL; Tampa M; Sarbu MI; Mitran MI; Mitran CI; Stoian AP; Diaconu CC; Paunica S; Georgescu SR
J Dermatolog Treat; 2020 Jun; 31(4):415-421. PubMed ID: 30897009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
